Metagenomi Therapeutics, Inc. (MGX)
| Market Cap | 53.99M |
| Revenue (ttm) | 25.21M |
| Net Income (ttm) | -87.87M |
| Shares Out | 37.62M |
| EPS (ttm) | -2.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,162 |
| Open | 1.450 |
| Previous Close | 1.480 |
| Day's Range | 1.430 - 1.480 |
| 52-Week Range | 1.250 - 3.950 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+596.86%) |
| Earnings Date | May 12, 2026 |
About MGX
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other... [Read more]
Financial Performance
In 2025, Metagenomi Therapeutics's revenue was $25.21 million, a decrease of -51.79% compared to the previous year's $52.30 million. Losses were -$87.87 million, 12.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 596.86% from the latest price.
News
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you ...
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investig...
Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing its lead gene-editing program MGX-001 for hemophilia A, targeting IND submission in Q4 and planning a global Phase I/II trial. Strong preclinical efficacy, robust safety, and strategic partnerships support a focused pipeline and long-term financial runway.
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to cre...
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 followin...
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative ...
Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Proprietary genome editing platform is advancing a lead hemophilia A program, MGX-001, with preclinical data showing curative, durable, and safe factor VIII expression. Pipeline expansion and Ionis partnership target additional indications, with key milestones set for 2025–2027.
Metagenomi to Present at Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative ...
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi, Inc. (NASDAQ:MGX) on Tuesday shared new dose range finding data from its MGX-001 hemophilia A program.
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions e...
Metagenomi taps Amazon's custom chips to develop gene-editing tools
Biotech firm Metagenomi said it is using artificial intelligence chips from Amazon.com's cloud computing unit to power some of its work in developing gene-editing technologies.
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0 million...
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients u...
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety prof...
Metagenomi to Present at Upcoming Scientific Meetings
EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its propriet...
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system wit...
Metagenomi Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
The conference highlighted advances in metagenomics-driven gene editing, with a lead hemophilia A program showing durable preclinical results and a robust pipeline supported by AI and strategic partnerships. IND filings are targeted for 2026, and financial runway extends into 2027.
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Appro...
Metagenomi Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Metagenomi showcased advances in metagenomics-driven gene-editing, highlighted robust preclinical data for hemophilia A and secreted protein disorders, and outlined a strategic roadmap with key regulatory and partnership milestones through 2026. Durability and specificity data de-risk lead programs.
Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...